19:39:40 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



Nervgen Pharma Corp
Symbol NGEN
Shares Issued 69,927,649
Close 2024-04-03 C$ 2.34
Market Cap C$ 163,630,699
Recent Sedar Documents

Nervgen Pharma prospectus offering

2024-04-03 20:43 ET - Prospectus Approved

The company's short form base shelf prospectus dated Aug. 12, 2022, was filed with and accepted by the TSX Venture Exchange, and filed with and receipted by the British Columbia Securities Commission, pursuant to the provisions of the Securities Act (British Columbia), and the Ontario Securities Commission, pursuant to the provisions of the Securities Act (Ontario), on Aug. 12, 2022. Under Multilateral Instrument 11-102, Passport System, the prospectus is deemed to have been filed with and receipted by each of the securities regulators in Alberta and Nova Scotia. The TSX Venture Exchange has also accepted the filing of the company's prospectus supplement dated March 25, 2024.

The TSX Venture Exchange has been advised that closing occurred on March 28, 2024, for gross proceeds of $23,011,788, including the full exercise of an overallotment option.

Agents:  Stifel Nicolaus Canada Inc., Canaccord Genuity Corp. and PI Financial Corp.

Offering:  8,515,000 units (Each unit consists of one common share and one-half of one common share purchase warrant of the company.)

Unit price:  $2.35 per unit

Warrant exercise price/term:  Each whole warrant is exercisable at $3 per share for 36 months from closing.

Agents' warrants:  170,127 non-transferable warrants, each exercisable to purchase one share at $2.35 per share for 36 months from closing

Overallotment option:  The agents were granted an option to purchase up to an additional 15 per cent of the units sold pursuant to the offering for a period of 30 days from and including the closing date. The overallotment option has been fully exercised for 1,277,250 units.

For further information, please refer to the company's prospectus supplement dated March 25, 2024, and the news releases dated March 21, 2024, and March 28, 2024.

© 2024 Canjex Publishing Ltd. All rights reserved.